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Bone Cements and Their Potential Use
in a Mandibular Endoprosthesis
Kok Weng Lye, B.D.S., M.D.S.,1 Henk Tideman, M.D., D.D.S., Ph.D.,1
Matthias A.W. Merkx, M.D., D.M.D., Ph.D.,2 and John A. Jansen, D.D.S., Ph.D.3
Bone cement was first used in the 1950s. Since then many modifications have been made and alternatives
developed to the original polymethylmethacrylate (PMMA) cement. In view of the use of bone cement in a novel
mandibular endoprosthetic system, we performed a review of the current literature on this material. Different
cements are described and their potential use in a mandibular endoprosthetic system discussed. The PMMA-
based cements are currently the most suitable choice. Plain PMMA has the longest track record and is the default
choice for the initial development phase of this system. If there is a significant risk of infection, then an antibiotic-
loaded PMMA cement can be selected. However, modified PMMA cements, composite resin cements, os-
teoinductive calcium phosphate compounds, and cementless fixation are options that offer advantages over
PMMA cements, and further research should be conducted to study their suitability.
Introduction
Polymethylmethacrylate (PMMA) was first used asbone cement in the 1950s when Sir John Charnley of the
University of Manchester successfully adapted it for the
cementation of an orthopedic prosthesis in a long bone.1 This
event revolutionized the treatment of joint disease. Since
then millions of cemented limb prostheses have been per-
formed, and the medical literature has documented their
phenomenal success.
However, cemented endoprostheses also have their share
of problems, as failure does occur and has been postulated to
be due to the PMMA cement. Infection and aseptic loosening
of the prosthesis are the most common complications that
necessitate prosthesis removal. As a result, there are concerns
regarding the shortcomings of PMMA cement, and research
into biologically superior cements over the last few decades
has led to the creation of other bone cements such as the
modified PMMA cements, calcium phosphate cements
(CPCs), glass-ionomer cements (GICs), and composite resin
cements (CRCs). Another research direction has led to the
creation of cementless arthroplasty, which is also widely used
and has shown considerable success. Yet another prospective
solution is the creation of an osteoinductive cement that
would have superior healing capability and bony integration.
All these advances have occurred mainly in the orthopedic
arena, and the application of bone cement in the field of cra-
niofacial surgery has been only for defect contour augmen-
tation.Recently, however, there has been interest inusingbone
cement for endoprosthetic replacement of the mandible.2
Significant mandibular defects may result from extensive
trauma, severe osteomyelitis, and ablative surgery for cancers
of the head and neck. These result in high morbidity, with
mastication, speech, and facial aesthetics being severely
compromised without appropriate reconstruction. The aims
of such mandibular reconstructions are to reestablish form
and function. This can be accomplished by anatomical resto-
ration of facial contours and framework and muscle re-
attachments. Currently, there are several reconstruction
techniques available for the treatment of the discontinuity
defect of the mandible, such as reconstruction plates, autog-
enous bone graft in customized trays,3 or microvascularized
bone flaps.4,5 The disadvantages of the current techniques are
donor site morbidity,6 infection, and failure of the bone graft.
Most efforts have focused on replacing the defects with vital
bone and tissues. This approach has an element of unpre-
dictability as there are many variables involved and various
complications often occur.7 The age of the patients, medical
problems, local healing potential, and source of bone graft are
all factors that make every case different and therefore less
predictable. As a result, other approaches are being explored.
In the field of tissue engineering, only two documented ex-
amples of using an engineered bone transplant to reconstruct
the mandible and maxilla have been published.8–10 This
method of reconstruction requires a period of implantation
for scaffold maturation in separate site and microsurgical
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transplantation after thematuration. Tissue engineering using
customized bone transplants will be the ideal solution, but its
routine clinical applications will not be available in the near
future. Therefore, the concept of an endoprosthetic modular
reconstruction of the mandible is a potentially viable option
that may eliminate the current problems faced by the other
techniques as such a device will be easily available and cost
effective.2 This novel approach follows the modular en-
doprosthetic reconstruction concept that has been routinely
used in limb-sparing surgery over the last two decades.11 This
technique involves the removal of all diseased bone and the
replacement of the missing portion of bone with an artificial
device fixated within the remaining bone. The modular sys-
tem combines standardized units to allow simplicity and
flexibility in the reconstruction of defects of various sizes. The
endoprosthesis equates to fixation of the prosthesis via ce-
mentation of an appropriate stem into the cancellous and
marrow space of the host bone (Figs. 1–3). The choice of ce-
ment for the novel system is vital for its success as it has to
provide the mechanical properties to allow the cement to act
as a grout for the transfer of forces and have good biocom-
patibility with both bone, dental and nerve tissues found in
the mandible. The cement also needs to exist in the in vivo
environment for long periods of time without degradation.
Among the many studies in the bone cement literature, none
covers the whole range of available materials. This review
article examines and presents an overview of the various
types of bone cements currently obtainable followed by a
discussion of their potential use in this new approach as well
as the prospective usage of tissue engineering techniques to
develop new cements that can overcome the weaknesses of
the current materials.
Plain PMMA Cement
Following Chanley’s success in using plain PMMA in total
joint replacements, the cement was used in other applica-
tions, such as fracture fixation, tumor surgery, and percuta-
neous vertebroplasty. The widespread acceptance of the
cement is a result of its simplicity of manipulation, low cost,
good physical strength, and ready availability. There has
been a consistently high tolerance to the material, and the
survival of cemented prostheses in the hip and knee using
PMMA bone cements is more than 90% after 15 years.12,13
More than 30 brands of plain PMMA cement are com-
mercially available and approved by the relevant regulatory
authorities of the United States and the United Kingdom.
They are similar in composition14 and include two compo-
nents, a powder and liquid, which are mixed together to
create the final cement. The powder portion comprises pre-
polymerized PMMA or a PMMA-based polymer, a radio-
pacifier of barium sulphate or zirconium oxide particles and
an initiator of benzoyl peroxide. The liquid portion com-
prises methyl methacrylate monomer, N,N-dimethyl-p-tolu-
idine, as an accelerator and hydroquinone as an inhibitor of
the polymerization reaction.
The mechanical characteristics of PMMA bone cement
around a cemented prosthesis allow the cement to evenly dis-
tribute the stresses and loads from the prosthesis to the bone.
The mechanical requirements for these systems are known
and all plain PMMA cements currently marketed meet the
main requirements of compressive strength >70MPa, tensile
FIG. 1. Modular mandibular endoprosthesis—apart (above)
and assembled (below). Color images available online at
www.liebertonline.com=ten.
FIG. 2. Fixation and assembly of the endoprosthesis after
2 cm segmental resection of the body of mandible. Color
images available online at www.liebertonline.com=ten.
FIG. 3. Radiograph of modular mandibular endoprosthesis.
Color images available online at www.liebertonline.com=ten.
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strength>50MPa, bending strength>50MPa, andmodulus of
elasticity >1800MPa.14 There are many other mechanical as-
pects to consider, and these are covered by technical publica-
tions that provide extensive descriptions of the mechanical
properties of the cements and their evaluation15,16; however, it
is out of the scope of this review to give further details.
Biologically, PMMA is considered to be inert and stable
(Fig. 4). It is insoluble and does not degrade over time and
function. PMMA was established very early on to have good
biocompatibility.17,18
There are, however, several documented shortcomings of
plain PMMA cement, which include: (1) lack of bioactivity
and bonding between the cement and bone, which results in
an intervening fibrous layer between the bone and PMMA,19
(2) thermal necrosis caused by a highly exothermic setting
reaction,20,21 (3) chemical necrosis and tissue toxicity due to
residual monomer and N,N-dimethyl-p-toluidine release,22
(4) a brittle material with insufficient fatigue resistance that is
susceptible to failure when tensile forces are present,15 and (5)
significant volumetric shrinkage of the cement during poly-
merization, which induces stresses and undermines the in-
tegrity of the cement–bone interface.23 The most common
cause of arthroplasties failure is aseptic loosening, which ac-
counts for almost two-thirds of the revision hip arthroplasties
and one-half of the revision knee arthroplasties.24 Although,
there is a multifactorial etiology for aseptic loosening, it has
been associated with the mechanical integrity and mechan-
ical properties of the PMMA bone cement. An important
parameter is the low impact and fatigue strength of the ce-
ment, which is especially crucial during functioning and
continuous exposure to tensile stresses. It has been demon-
strated under in vivo conditions that porosity is the major
factor influencing the mechanical behavior of bone cement.25
The next step in the evolution of PMMA cement was the
development of antibiotic-containing cements in 1969 by
Buchholz26 on the basis that a deep infection following total
joint replacement is a devastating complication for the pa-
tient. The diagnosis of a mild infection is difficult,27 isolation
of the causative organism is problematic,28,29 systemic anti-
biotics are ineffective,30,31 and treatment usually requires
multiple operations, with amputations and mortality some-
times unavoidable.32,33 The addition of antibiotics to a
PMMA cement and their subsequent release enable a high
concentration of antibiotics in the vicinity of the implant.34
Since their inception, antibiotic-loaded PMMA cements have
become the standard of care in western Europe, including the
United Kingdom and Scandinavia. There is good evidence of
their efficacy and advantage over plain PMMA cements in
reducing primary infections and improving the success rate
in revision cases.35–37 Currently, in most parts of the world
except the United States, these cements are used both pro-
phylactically in primary arthroplasties and revision surgery.
Based on its pharmacological properties, gentamicin was
the first and is still the most common antibiotic incorporated
into bone cements. Studies have shown that the antibiotic is
released at high concentrations during the early stage after
implantation. One study found evidence of significant level
of gentamicin level in the immediate surrounding tissue
(150mg=mL) up to 5.5 years after implantation.38 Other an-
tibiotics less commonly used are tobramycin, vancomycin,
fusidic acid, erythromycin with colistin and clindamycin.
The addition of an antibiotic does affect the physical and
mechanical properties of the cements, but they are still
within the clinical requirements.14
Although the incorporation of antibiotics into bone ce-
ments has raised concerns about such issues as the induction
of antimicrobial resistance, allergic reactions, toxic side ef-
fects, mechanical deterioration of the cement, and prolonged
release of subtherapeutic levels of antibiotics,39 there is no
evidence of any significant problem.
In summary, PMMA cement and its antibiotic-containing
formulations are well established and the gold standard to
which all other bone cements must be compared. They
should be the default cements chosen for any new approach.
The choice between a plain and an antibiotic-loaded PMMA
is not so clear. There are different practices in different
geographical regions. In the United States, antibiotic-loaded
cements are cleared for use only in revision arthroplasties,37
whereas they are routinely used in primary arthroplasties in
some European countries. Thus, the clinicians must consider
the accepted practices of the region and the risk factors of
individual patients before selection of the cement. There are
some published guidelines on this matter.37
Modified PMMA Cement
Although PMMA has had wide acceptance and historical
success as a prosthetic cementation material, its inherent
FIG. 4. Light micrograph showing polymethylmethacrylate
(PMMA) installed in the cortical bone of a goat tibia showing
PMMA being surrounded by a thin fibrous capsule. The
Scale bar represents 200micrometers. Color images available
online at www.liebertonline.com=ten.
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problems have long been criticized. The principal reason for
cemented arthroplasty revision is aseptic loosening after
long-term implantation, which accounts for approximately
75% of all failed primary total hip joint replacements.40,41 The
main mechanism is fatigue crack propagation in the cement,
which initiates from ‘‘weak zones,’’ that is, the bone–cement
interface, cement–prosthesis interface, or the particles within
the cement mantle, under cyclical loading.16,42 This me-
chanical failure then produces particles or debris that are
phagocytized by macrophages, which in turn produce tumor
necrosis factors that cause bone resorption and aseptic
loosening.43 The main reason for this phenomenon is the lack
of bioactivity of PMMA cement.44 Therefore, there is no
bone–cement bonding and no direct transfer of forces from
the cement to the bone. This issue has prompted the devel-
opment of modified PMMA cement formulations.
Numerous approaches to improve PMMA cement have
been proposed, and much research has been conducted,
producing many modifications with good potential. Some
published reviews have comprehensively described these
strategies.45–47 Table 1 summarizes the different problems
targeted and the solutions and approaches used to modify the
cement. There are also many combinations of the different
approaches to simultaneously solve multiple problems,
whicharebasedon thedifferent applications of the cement and
the characteristics desired for a particular purpose. The most
popular modified PMMA cements in recent years are the al-
ternative radiopacifier cements, bioactive cements, andhydro-
philic, partiallydegradableandbioactive cements.45However,
formostofthesemodifiedcements,completeinformationabout
their optimum proportion, complex mechanical characteris-
tics, biocompatibility, and long-term stability is unavailable.
Hence, although this category of cements has much potential,
presently there is no proof of their long-term success.
Calcium Phosphate Cement
Calcium phosphate cement is a blend of various calcium
phosphate powders that form an apatite phase or brushite
when they set.97 CPC that forms hydroxyapatite (HA) during
hardening is called apatite cement, and CPC that forms
brushite during setting is called brushite cement.98 The
original CPC formulation was developed by Brown and
Chow (U.S. Patent No. 4,518,430).99 The setting of CPC is
based on a dissolution–reprecipitation mechanism, which is
induced by mixing calcium phosphate powders with a liquid
phase. The precipitated crystals interlock to form a hard
mass.98 The advantages of CPC are the slow exothermic re-
action and setting without shrinkage. In addition, its com-
position is similar to that of bone, and it possesses excellent
bone biocompatibility (Fig. 5). The use of a bioactive material
capable of releasing calcium and phosphate ions has the
potential to promote osteoconduction. Studies show bone
growth on the surface and into the pores of this material after
implantation.100 As a result of its great potential as a grafting
material, a large number of CPC formulations have been
prepared and studied for possible clinical applications. In the
field of dentistry, oral surgery, and craniofacial surgery,
CPCs have been found to be useful grafting materials for
periodontal, jaw, and craniofacial defects.101–104
All CPCs consist of a solid and a liquid component. The
solid component consists of two or more calcium phosphate
compounds, whereas the liquid component can be water,
saline, or sodium phosphate. The combination of the two
components in a specific proportion results in a phase trans-
formation with the calcium phosphate dissolving and then
precipitating into a less soluble calcium phosphate, which
is determined by the pH of the cement setting reaction.105
Mechanically, CPCs have a compressive strength equal to or
greater than bone, but a significantly lower tensile strength
(1–10MPa). Therefore, CPCs can be used only in non- to low-
loadbearing applications, such as cranioplasty, facial con-
touring, and periodontal defects. Their use has also yielded
good results in the fixation of bone fractures.106,107 A study that
attempted to use CPC to fix titanium implants found that the
material was biocompatible and osteoconductive, but that
the load failure values when using CPC as a grout were sig-
nificantly lower than those of PMMA.108 Numerous attempts
have been made to improve CPCs via such methods as (1)
optimization of osteoconduction through the creation of
pores109 (Fig. 6), (2) improvement of the strength of the ce-
ment through the incorporation of various fillers,110,111 and (3)
applications for delivery of therapeutic molecules such as
antibiotics, anti-cancer drugs, and anti-inflammatories.112,113
The few CPCs commercially available, Norian Skeletal Repair
System (Synthes, Inc., West Chester, PA), BoneSource
(Stryker, Kalamazoo, MI), and a-Bone Substitute Material
(Etex Corporation, Cambridge, MA), are only recommended
for nonweight-bearing applications.
CPC can also be used for the manufacturing of ceramic
scaffolds with precise dimensions and predetermined struc-
ture. Currently, rapid prototyping techniques are used to
make customized scaffolds. These methods are based on
extrusion freeforming or fugitive wax molds, which is fol-
lowed by a sintering process.114,115 The procedure makes use
of an aqueous calcium phosphate slurry. Self-setting CPC
can be used as replacement of the slurry, which would make
the production process easier, as sintering of the scaffold is
no longer required.
In summary, CPCs have been proven effective in clinical
applications in nonload-bearing situations and maxillofacial
and craniofacial surgery. Novel formulations with different
modifications are actively being researched and improvements
have beenmade in themechanical and biological properties of
this family of cements. Thus, in the not-too-distant future, a
product may exist that can handle a load-bearing situation
and confer all the other biological advantages of CPC. The tis-
sue engineering approach utilizing calcium phosphate–
derived scaffolds with stem cells or osteoinductive proteins
is a promising method in the future, but there are some im-
portant issues that need to be studied before this can occur.
Calcium Sulfate Cement
This cement, also known as gypsum or plaster of Paris, has
been used extensively in dentistry and as a bone graft sub-
stitute in 1961 by Peltier.116 For its preparation, calcium sul-
fate powder is mixed with water, resulting in crystallization.
This process is random and the final product contains many
defects. Surgical-grade calcium sulfate cements (CSCs) in-
volve the use of calcium sulfate hemihydrate.117 CSC inhibits
fibrous tissue ingrowth and encourages angiogenesis and
osteogenesis because of its mild acidic environment and
gradual resorption.118 The resorption of the cement occurs via
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dissolution and is complete in about 2months.119 Studies have
shown that CSC is bone biocompatible and comparable to au-
togenous bone in healing rate when used as a bone graft sub-
stitute and bone void filler in animal defect models.120
However, its very rapid resorption and low compressive
strength are shortcomings that hamper the clinical application
of CSC.121 Another innovation is the addition of an antibiotic in
CSC, which makes it effective in the treatment of acute bone
infections associated with bone loss. Mechanically, a commer-
cial CSC formulation (MIIGX3; Wright Medical Technology,
Arlington, TN) has been reported to achieve a reasonable
compressive (*96MPa) and tensile (*16MPa) strength.122
CSC has shown good promise as a bone defect filler and
bone substitute, with good biocompatibility and resorptive
capability to allow bony ingrowth and replacement. How-
ever, the mechanical properties of the cement do not measure
up in load-bearing situations. Further, the cement frequently
undergoes too rapid a rate of resorption, which means in-
sufficient bony ingrowth and replacement, early loosening of
the cemented prosthesis and therefore, failure.
Table 1. Problems Targeted and Strategies to Improve Polymethylmethacrylate Cement
Problem targeted Category of cement Approach used
Poor adhesion Cross linked Add triethylene glycol dimethacrylate48,49
Add ethylene glycol dimethacrylate48,49
Add poly (ethylene glycol) dimethacrylate48,49
Solid phase Partial replacement of MMA by hydroxypropylmethacrylate50
Improved adhesion Use tributyl borane and partially replace MMA with
4-trimethacryloyloxyrthyl trimellitate51
Add 3-methacryloxyproyl-trimethoxysilane52
Inert cement Bioactive Add hydroxyapatite53=apatite wollastonite glass54=recombinant
human growth hormone55=hydroxyapatiteþ chitosan56
Add the above with an additional polymer (bispheno glycidyl
dimethacrylate57=PEMA56=PEMA with n-butyl methacrylate58=4
META-PMMA59=methacrylic acid60=diethyl aminoethyl
methacrylate61)
Add 3-methacryloxyproyl-trimethoxysilane=3-aminopropyltriethoxysilane=
3-glycidoxypropyltrimethoxysilane=soluble calcium salt62,63
Lack of
degradability
Partially degradable Use poly (hydroxyalkenoate)=poly ({R}-3-hydroxybutyrate)=
PMMA-graft-poly ({R}-3-hydroxybutyrate)64,65
Biodegradable Add cancellous bone66=nanosized Al2O3
45=b-TCP67=
sodium fluoride68=a-TCP69=chitosan microspheresþ b-TCP70
Add epoxy-SiO2
71=micro- or nanosized TiO272=chitosan
56 and an
additional polymer (bisphenol glycidyl dimethacrylateþ triethylene
glycol dimethacrylateþMMA71=PEMA45=DEAEMA61)
Highly exothermic
reaction
Modified monomer Add a comonomer that dissolves in MMA73
High elastic modulus Reduced modulus Use polybutyl methacrylate instead of PMMA45
Use PEMA with n-butyl methacrylate74
Low tensile strength,
fracture toughness,
and fatigue life
Reinforced Add fibers of graphite75=stainless steel76=titanium77=Kevlar 2978=
polyethylene79=ultrahigh-molecular weight polyethylene80
Add particulates of rubber-toughened PMMA powder81=poly
(isobutylene)82=acrylonitrile-butadiene-stryene83=poly
(caprolactone)84=polybutyl methacrylate45=alumina powder85=
chitosan86
Add carbon nanotubes87
Toxicity of DMPT Reduced DMPT Reduce DMPT by 50%88
Solution to solution Two PMMAs predissolved in MMA solutions89
Antioxidant Add vitamin E90
Alternative
accelerator
Use a higher molecular weight accelerator45=polymerizable tertiary
amines91=tertiary amine with long-chain fatty acid92
Nonuniform dispersal
of barium sulphate
or zirconium oxide
Uniformly dispersed
radiopacifier
Use nanosized barium sulphate45
Toxicity of
radiopacifier
Alternative
radiopacifier
Use a bromine-containing chemical45
Iodine-containing chemical93
Bismuth compound94
Tantulum powder95
Heavy metal–containing organic material96
MMA, methylmethacrylate; PMMA, polyMMA; DMPT, N,N-dimethyl-p-toluidine; PEMA, polyethyl methacrylate; b-TCP, b tricalcium
phosphate.
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Glass-Ionomer Cement
GIC, also known as polyalkenoate cement, was originally
developed as a dental restorative material. It has been very
successful as it is highly biocompatible and shows beneficial
properties, such as adhesion to tooth structure and release of
fluoride ions, which confers resistance to caries. As a result,
the development of GIC for medical usage has been sug-
gested.123 Interest in medical applications of GIC has been
generated for it possesses unique properties that give it ad-
vantages over PMMA cement.
The setting reaction of GIC occurs through the transfer of
ions from the glass to the matrix. This reaction is not exo-
thermic, which eliminates the risk of thermal damage to the
surrounding tissue and also allows the cement to be a drug
delivery system through the provision of temperature-
sensitive drugs. Second, GIC does not have any volumetric
shrinkage on setting. Third, this cement is able to bond to
bone and metals, which means that there is chemical bond-
ing in addition to the normal mechanical interaction on
which PMMA relies. Last, the cement exhibits osteoconduc-
tive properties after implantation in bone, in contrast to
bioinert plain PMMA.
However, the mechanical properties of GIC have proven
to be adequate only for low to moderate load-bearing ap-
plications. In addition, more recent studies that have focused
on the biocompatibility of GIC have reported in vitro toxicity
reactions that have been linked to fluoride ion release, the
release of aluminum from the cement, and the low pH of the
cement during setting and maturation.124 In vivo studies
have yielded better results, with extensive bone formation on
the GIC surface. Studies have also reported adverse effects of
GICs on nerve function,125,126 which contraindicates the use
of GICs in situations with exposed nerves and neural tissues.
Unfortunately, this effect was unknown to others, resulting
in four cases of post-otoneurosurgery aluminum encepha-
lopathy127 and a case of facial nerve paralysis.128
Clinical use of the material has had mixed success. GIC
has performed well in otorhinolarnygolical applications, but
not when used as an allograft bone expander or in revision
arthroplasty. Early reloosening has been found as well as
aluminum in the surrounding bone. Therefore, it is con-
cluded that the GICs currently available are not suitable in
load-bearing situations. However, research has led to the
improvement of the physical properties of GIC, with resin-
modified versions, highly viscous cements, and the addition
of filler particles such as HA.129,130
In view of these findings, no GIC currently exists that is
suitable for cementation of an endoprosthetic system. The
main concerns are the mechanical properties of the cement in
load-bearing situations and possible biocompatibility issues,
as there is an abundance of nerves and other highly spe-
cialized dental tissues in the region.
Composite Resin Cement
Dental composite resins are composed of a resin matrix
that is mixed with other materials to produce properties
superior to the individual components. The first particulate-
filled composite was patented in 1951 by Knock and
Glenn.131 This was further improved by Bowen, and a new
resin, bisphenol glycidyl dimethacrylate (BIS-GMA), was
FIG. 5. Calcium phosphate cement installed in the cortical
bone of the tibia of a goat. At the cement–bone interface, new
bone was deposited. In addition, degradation of the cement
can be observed, which was due to cellular activity. The scale
bar represents 200 micrometers. *Remodeling lacuna. Color
images available online at www.liebertonline.com=ten.
FIG. 6. Light microgram showing injectable calcium phos-
phate cement (CPC) provided with poly(lactic-co-glycolic
acid) (PLGA) microparticles, 4 weeks after implantation
degradation of the microparticles occurred associated with
the ingrowth of new bone and additional degradation of
the calcium phosphate cement. Color images available online
at www.liebertonline.com=ten.
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patented in 1962, in which the silica filler particles were
treated with vinylsilane to allow their chemical bonding to
the resin matrix.132 This material was widely accepted as a
dental restorative material and is the basis for the current
composite resins of today.
A composite resin consists of four main components: an
organic resin matrix, an inorganic filler, a coupling agent that
creates bonding between the inorganic and organic compo-
nents, and an initiator=accelerator, which results in the cur-
ing of the material. In modern dental composites, the resin
matrix comprises BIS-GMA, urethane dimethacrylate, and
triethylene glycol dimethacrylate. These components were
developed to replace the methylmethacrylate in acrylic resin
and boast several advantages, such as reduced polymeriza-
tion shrinkage, quick setting, and superior hardness. This
resin matrix is then highly reinforced with filler particles to
give rigidity, increased tensile and compressive strength,
decreased polymerization shrinkage, a decreased coefficient
of thermal expansion, decreased water sorption, an increased
modulus of elasticity, and abrasion resistance. Silicates and
glasses of different sizes are used as filler particles.
Fiber-reinforced composites have been developed for bone
fixation and load-bearing implants.133 Bone fixation devices
made from fiber-reinforced composites have been shown to
be well adapted to bone and offer stiffness and strength.133
Carbon fiber-reinforced composites also demonstrate good
biocompatibility and have been found to perform well as
intervertebral implants and bone fixation screws. Fixation
plates made from this material can even rival their titanium
counterparts.133 Other developments have produced differ-
ent composites that are tailored for various applications in
the area of orthopedic implants and bone-grafting materials.
As for cementation purposes, HA composite resin is a
CRC that has been developed as an alternative to PMMA for
the stabilization of fractures during cancellous screw fixa-
tion.134 The cements combine HA with three acrylic mono-
mers, of BIS-GMA, 2,2 bis-(4-methacryloyloxyethoxyphenyl)
propane, and triethylene glycol dimethacrylate. Studies have
shown that HA CRC has high compressive strength, mini-
mally exothermic polymerization, and good biocompatibili-
ty.134,135 CRCs used in vertebroplasty also demonstrate good
mechanical properties, bioactivity, and direct bone apposi-
tion on the cement.136,137 One such commercially available
product is Cortoss (Orthovita Malvern, PA).
Although studies have shown the good biocompatibility
of CRCs, there are controversial biological issues related to
the composite materials. Bisphenol-A, a precursor of BIS-
GMA, has been found to be estrogenic.138,139 Although BIS-
GMA does not stimulate the progesterone receptors of breast
cancer, there are reservations about long-term effects due to
the chemical components that do leach out and accumulate
in local and distant tissues.140,141
The literature has shown that CRCs are good potential
candidates for the cementation of an endoprosthesis and
have several advantages over conventional PMMA cement.
However, the products of biodegradation from the cement
and their by-products may have long-term effects on the
surrounding tissues and organs. These effects occur espe-
cially when CRCs are applied in load-bearing situations,
which can result in increased degradation of the cements
because of stress and motion.
Cementless Fixation
In the 1970s, researchers assumed that premature loosen-
ing and failure of cemented prostheses were related to ‘‘ce-
ment disease.’’142,143 As a consequence, some investigators
directed their research and development efforts toward
prostheses that do not require any cementation. Cementless
fixation was achieved by the application of surface-coated
implants that provide initial stability and allow osseous in-
growth onto and into the prostheses. The biological fixation
of the implant to the bone that is finally obtained allows the
transmission of forces across the interface.144,145 There is
growing interest in this method as it preserves bone stock
and eliminates the use and disadvantages of cement.
The most frequently used approach to modify the bone-
bonding capacity of an endoprosthesis is the application of a
calcium phosphate coating by plasma spraying.
Calcium phosphate coatings have been shown to be non-
toxic, nonallergenic, and noninflammatory.146,147 These bio-
active coatings encourage the growth and apposition of bone
along the implant surface.148,149 Although meta-analysis
shows that cemented total hip replacements still demonstrate
better survival, uncemented implants are continuously im-
proving with changes in their design.150 Comparative studies
between cemented and uncemented fixation are still limited
and provide only medium-term data (5–10 years).151,152
Long-term evaluation is required to determine whether ce-
mentless fixation offers any significant advantages with re-
gards to prosthesis survival and revision complexity over
cemented fixation.
Cementless fixation is a potentially viable option for the
fixation of a mandibular endoprosthesis, but the design of
the prosthesis is critical as the mandible has a varying cur-
vature and cross-sectional area at different locations. The
stem of the prosthesis needs to be customized to provide a
precise fit and have a sufficiently large surface area to pro-
vide adequate immobilization during fixation and early
function.
Osteoinductive Bone Cements
All the cements mentioned in the above sections are either
inert or osteoconductive. However, the endoprosthetic sys-
tem may be used in areas or tissues that are compromised,
such as irradiated tissues after oncologic treatment. In these
circumstances, osteoinductivity of the cement is desired as it
can recruit the pluripotent cells from surrounding tissues
and stimulate their differentiation into osteoprogenitor
cells.153 This will promote the rate of bone healing in normal
situations and improve the success in unfavourable regions.
The phenomenon is shown by certain biomaterials that
stimulate bone deposition even when placed in ectopic sites
away from the skeleton, but the principle has been largely
unexplainable.154,155
CPCs and ceramics have been reported to possess os-
teoinductive properties.154,156,157 They showed bone forma-
tion in the pores of porous calcium phosphate biomaterials.
However, not all calcium phosphate compounds exhibit this
behaviour. Pertinent studies concluded that the factors crit-
ical to the osteoinductivity of the biomaterials are as follows:
(1) chemistry, (2) sintering temperature, (3) material disso-
lution, (4) three-dimensional topography, (5) microporosity,
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(6) macroprosity, and (7) the animal model studied.153,154 It is
only when the biomaterial fulfills all the required criteria that
bone induction will occur. There are also attempts to augment
the osteoinductivity by incorporating bone morphogenetic
proteins, which are well-recognized bone-inductive proteins,
into the biomaterials. In animal studies, superior osteoin-
ductivity has been shownwhen bonemorphogenetic proteins
are loaded onto the calcium phosphate biomaterials.158–161
Nevertheless, the creation of osteoinductive biomaterials still
needs optimization and customization for each different ap-
plication. For example, endoprosthesis cementation requires a
material that shows structural integrity and mechanical
strength primarily in addition to the osteoinductivity.
Conclusions
Several bone cements are available, but currently only
PMMA-based cements are appropriate for use in the pro-
posed mandibular endoprosthetic system. Plain PMMA has
the longest track record and is still the default choice for the
initial development phase of this therapy. If there is a signif-
icant risk of infection, then an antibiotic-loaded cement
should be selected. However, modified PMMA cements,
CRCs, and cementless fixation options have to be studied, and
the creation of new osteoinductive cements that have favor-
able bone response, partial resorption with bone ingrowth,
and stronger bone-cement bonding is important to ensure
better success of the novel mandibular endoprosthetic system.
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